About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Media & Investor Contacts:
Head of Capital Markets & Investor Relations
+64 (0) 27 807 8073
Senior Communications and Investor Relations Manager
+64 (0) 22 511 4050
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.
Attached to this news release are the following additional documents:
Constant Currency Information
Constant currency information included within this news release is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company’s comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A constant currency analysis is included on page 15 of the company’s Interim Report 2024, and the company’s constant currency framework can be found on the company’s website at www.fphcare.com/ccf.
Half Year Results Conference Call
Fisher & Paykel Healthcare will host a conference call on Wednesday, 29 November 2023 to discuss the half year result. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT (4:00pm USEST, Tuesday 28 November) and will be simultaneously broadcast online.
To listen to the webcast, access the company’s website at www.fphcare.com/investor. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.
To listen and participate in the conference call via phone, please register via ‘GlobalMeet’ by clicking this link. Once registered, click ‘Call Me’ and you will receive a phone call connecting you through to the conference line.
Fisher & Paykel Healthcare announces results for the first half of the 2024 financial year
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Noninvasive respiratory support that provides a continuous distending pressure
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment